Kieran Gallahue
Known title: DirectorCIK: 0001308428
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
Transaction History
| NVST | ▲ Buy | Grant | 9,330 | $0 | 5/19/2026 | View on chart |
| EW | ▲ Buy | Grant | 3,251 | $0 | 5/8/2026 | View on chart |
| EW | ▲ Buy | Grant | 1,064 | $0 | 5/8/2026 | View on chart |
| NVST | ▲ Buy | Grant | 10,450 | $0 | 6/10/2025 | View on chart |
| EW | ▲ Buy | Grant | 3,528 | $0 | 5/9/2025 | View on chart |
| EW | ▲ Buy | Grant | 1,154 | $0 | 5/9/2025 | View on chart |
| NVST | ▲ Buy | Grant | 10,085 | $0 | 5/21/2024 | View on chart |
| EW | ▲ Buy | Grant | 3,055 | $0 | 5/8/2024 | View on chart |
| EW | ▲ Buy | Grant | 999 | $0 | 5/8/2024 | View on chart |
| EW | ▲ Buy | Option Exercise | 7,056 | $260K | 2/23/2024 | View on chart |
| EW | ▼ Sell | Gift | 7,056 | $0 | 2/23/2024 | View on chart |
| EW | ▼ Sell | Gift | 7,056 | $0 | 2/23/2024 | View on chart |
| EW | ▼ Sell | Open Market | 3,058 | $268K | 2/23/2024 | View on chart |
| NVST | ▲ Buy | Grant | 5,425 | $0 | 5/23/2023 | View on chart |
| EW | ▲ Buy | Grant | 2,803 | $0 | 5/12/2023 | View on chart |
| EW | ▲ Buy | Grant | 898 | $0 | 5/12/2023 | View on chart |
| NVST | ▲ Buy | Grant | 4,435 | $0 | 5/24/2022 | View on chart |
| EW | ▲ Buy | Grant | 2,300 | $0 | 5/4/2022 | View on chart |
| EW | ▲ Buy | Grant | 737 | $0 | 5/4/2022 | View on chart |
| EW | ▲ Buy | Option Exercise | 32,256 | $719K | 2/8/2022 | View on chart |
| EW | ▼ Sell | Open Market | 32,256 | $3.6M | 2/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Piper Sandler cuts Envista price target to $26, maintains Neutral
Piper Sandler recently lowered its price target for Envista Holdings to $26 while keeping a Neutral stance. This move aligns with the stock's current trading level near its 52-week low of $18.77. The company has also scheduled its third-quarter 2026 earnings call, which will provide updated financial insights.
Piper Sandler cuts Envista price target to $26, maintains Neutral. Piper Sandler recently lowered its price target for Envista Holdings to $26 while keeping a Neutral stance. This move aligns with the stock's current trading level near its 52-week low of $18.77. The company has also scheduled its third-quarter 2026 earnings call, which will provide updated financial insights.